Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Notes Payables (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed Notes Payables for 15 consecutive years, with $105000.0 as the latest value for Q4 2025.

  • Quarterly Notes Payables fell 24.46% to $105000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $105000.0 through Dec 2025, down 24.46% year-over-year, with the annual reading at $105000.0 for FY2025, 24.46% down from the prior year.
  • Notes Payables hit $105000.0 in Q4 2025 for Guided Therapeutics, down from $411000.0 in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $421000.0 in Q2 2025 to a low of $11000.0 in Q1 2021.
  • Historically, Notes Payables has averaged $109558.9 across 5 years, with a median of $59000.0 in 2023.
  • Biggest five-year swings in Notes Payables: plummeted 98.51% in 2021 and later soared 452.94% in 2023.
  • Year by year, Notes Payables stood at $48000.0 in 2021, then increased by 17.85% to $56569.0 in 2022, then grew by 4.3% to $59000.0 in 2023, then skyrocketed by 135.59% to $139000.0 in 2024, then decreased by 24.46% to $105000.0 in 2025.
  • Business Quant data shows Notes Payables for GTHP at $105000.0 in Q4 2025, $411000.0 in Q3 2025, and $421000.0 in Q2 2025.